OMTN, Volume 19

Supplemental Information

Binding and Structural Properties

of DNA Aptamers with VEGF-A-Mimic Activity

Toru Yoshitomi, Misako Hayashi, Takumi Oguro, Keiko Kimura, Fumiya Wayama, Hitoshi Furusho, and Keitaro Yoshimoto

1	Supporting information
2	
3	
4	Binding and structural properties of DNA aptamers with VEGF-A-
5	mimic activity
6	
7	Toru Yoshitomi ¹ , Misako Hayashi ¹ , Takumi Oguro ¹ , Keiko Kimura ¹ , Fumiya Wayama ¹ ,
8	Hitoshi Furusho ² , and Keitaro Yoshimoto ^{*,1,3}
9	
10	¹ Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo,
11	Komaba 3-8-1, Meguro-ku, Tokyo 153-8902, Japan
12	² Chemical General Division, Nissan Chemical Industries, Ltd., 2-10-2 Tsuboi-nishi, Funabashi,
13	Chiba 274-8507, Japan
14	³ JST, PRESTO, The University of Tokyo, Komaba 3-8-1, Meguro, Tokyo 153-8902, Japan
15	
16	*Corresponding author: Keitaro Yoshimoto, Ph.D., Department of Life Sciences, Graduate
17	School of Arts and Sciences, The University of Tokyo, Komaba 3-8-1, Meguro, Tokyo 153-
18	8902, Japan
19	
20	Phone and FAX: +81-3-5454-6580
21	E-mail: <u>ckeitaro@mail.ecc.u-tokyo.ac.jp</u>
22	

Selection		MB	[MB]	[ssODN]	Incubation	Number of	Washing	
cycle	round		(µg)	(μM)	volume (µL)	wasnes	volulile (µL)	
1	1	MB1		0.64			200	
	2	MB2		0.25		3		
2	3	MB1	о г	0.28	20			
	4	MB2	0.5	0.15	20			
3	5	MB1		0.17				
	6	MB2		0.21				

Table S1. In vitro selection conditions

Selection		Number of Sequence (5' to 3')		Ranking	Counting	Total counting	Total abundance	
cycle	target	total reads			number	number	ratio (%)	
	VEGFR-1	32,984	Not found	-	ND	ND	0	
1								
	VEGFR-2	52,245	GTCGTGTTTGTTGTTGTTTTCATTTTTGCGGCCCC	5 th	3	3	0.06	
			GTCGTGTTTGTTGTTGTTTTCATTTTTGCGGCCCC	2 nd	185			
			GTCGTGTTTGTTGTTGTTTTCATTTTTGCGGCC	5 th	90			
	VEGFR-1	32 173	GTCGTGTTTGTTGTTGTTTTCATTTTTTGCGGCC	42 nd (tie)	6	287	0.892	
		0=,0	GTCGTGTTTGTTGTTGTTTTCATTTTTTGCGGCCC	42 nd (tie)	6		0.00 -	
2			GTCGTGTTTGTTGTTGTTGTTGTGGCCC	757 th (tie)	1			
			GTCGTGTTTGTTGTTGTTTTCGATTTTTGCGGCC	757 th (tie)	1			
			GTCGTGTTTGTTGTTGTTTTCATTTTTGCGGCCC	4 th	60			
	VEGFR-2	34,000	GTCGTGTTTGTTGTTGTTTTCATTTTTGCGGCC	8 th	29	90	0.26	
			GTCGTGTTTGGTTGTTTGTTTCATTTTTGCGGCC	1459 th	1			
			GTCGTGTTTGTTGTTGTTTTCATTTTTGCGGCCC	2 nd	238			
			<mark>GTCGTGTTTGTTGTTGTTTTC</mark> ATTTTTG <mark>C</mark> GG <mark>CC</mark>	10 th	82			
	VEGFR-1	GT <mark>C</mark> GTGTTT FR-1 22,093 GT <mark>CGTG</mark> TTT GT <mark>C</mark> GTGTTT	GTCGTGTTTGTTGTTGTTTTCATTTTTTGCGGCCC	42 nd	8			
3				GTCGTGTTTGGTTGTTTGTTTTCATTTTTGCGGCCCC	72 nd	5	351	1.59
			GTCGTGTTTGTTGTTGTTTTCATTTTTTGCGGCC	103 rd	4			
			GTCGTGTTTGTTGTTGTTTCATTTTTGCGGCC	278 th (tie)	2			
			GTCGTGTTTGTTGTTGTTTCATTTTCGCGGCCC	278 th (tie)	2			
			GTCGTGTTTATTGTTGTTTTCATTTTTGCGGCCC	819 th (tie)	1			

Table S2. Abundance distribution of Apt01 families (5'-X<u>GTCGTGTTTGTTGTTGTTGTTTCATTTTGCGGC</u>XXXX-3') at each round.

		GTCGTGGTTTGTTGTTGTTTTCATTTTTGCGGCC	819 th (tie)	1		
		GGTCGTGTTTGTTGTTGTTTTCATTTTTGCGGCCC	819 th (tie)	1		
		GTCGTGTTTGTTGTTGTTTTCATTTTTGCTGCCC	819 th (tie)	1		
		GTCGTGTTGTTGTTGTTTTCATTTTGGCGGCC	819 th (tie)	1		
		GTCGTGTTTGTTGTTGTTTTCATTTTGCGGCC	819 th (tie)	1		
		GTCGTGTTTGTTGTTGTTTTCGATTTTTGCGGCCC	819 th (tie)	1		
		GTCGTGTTTGTTGTTGTTTTCATTTTTGCGGCC	819 th (tie)	1		
		GTC GTTTTTGTTGTTGTTTCATTTTTGCGGCCC	819 th (tie)	1		
		GTCGTGTTTGTTGTTGTTTTCATTTTTGCGGCCC	5 th	165		
		GTCGTGTTTGTTGTTGTTTTCATTTTTGCGGCC	7 th	86		
		GTCGTGTTTGTTGTTGTTTTCATTTTTTGCGGCC	51 st	5		
		GTE GTGTTTGTTGTTGTTGTGTGTGCGCCCC	65 th	4		
VEGFR-2	24,684	GTCGTGTTTGGTTGTTGTTTTCATTTTTGCGGCCC	98 th	3	266	1.07
		GGT <mark>G</mark> GTGTTTGTTGTTGTTTTCATTTTTGGCGGCCC	824 th (tie)	1		
		GTCGTGTTTGGTTGTTGTTTTCATTTTTGCGGCCT	824 th (tie)	1		
		GTCGTGTTTGTTGTTTGTTTTCATTTTTGCGGTCC	824 th (tie)	1		

Selection		Number	Sequence (5' to 3')	Ranking	Counting	Total counting	Total abundance
cycle	target	of total reads			number	number	ratio (%)
	VEGFR-1	32,984	Not found	-	ND	ND	ND
1							
	VEGFR-2	52,245	Not found	-	ND	ND	ND
			G <mark>CTGATAGGATGGGTTGTAGGTC</mark> TAGGGGGGGGG <mark>CC</mark>	23 rd	14		
	VEGFR-1	32,173	GCTGATAGGATGGGTTGTAGGTCTAGGGGGGGGGGGG	38 th	7	22	0.068
			G <mark>CTGATAGGA</mark> TGGG <mark>TTGTAGGTC</mark> TAGGGGGGGG <mark>CC</mark>	772 nd	1		
2							
			G <mark>CTGATAGGAT</mark> GGG <mark>TTGTA</mark> GGT <mark>C</mark> TAGGGGGGGGG <mark>CC</mark>	14 th	18		
	VEGFR-2	34,000	GCTGATAGGATGGGTTGTAGGTCTAGGGGGGGGGGGG	16 th	11	30	0.088
			G <mark>CTGATAGGA</mark> TGGG <mark>TTGTAGGTC</mark> TAGGGGGGGG <mark>CC</mark>	1,014 th	1		
			G <mark>CTGATAGGA</mark> TGGG <mark>TTGTAGGTC</mark> TAGGGGGGGGG <mark>CC</mark>	22 nd	18		
			G <mark>C</mark> TGATAGGA <mark>T</mark> GGGTTGTAGGTATAGGGGGGGGG <mark>CC</mark>	819 th (tie)	1		
	VEGFR-1	22,093	G <mark>C</mark> TGATAGGATGGGTTGTAGGTCTAGAGGGGGGGCC	819 th (tie)	1	22	0.10
			GCTGATAGGATGGGTTGTAGGTCTAGGGGGGGGGGGCC	819 th (tie)	1		
з			GETGATAGGATGGGTTGTAGGTCTAGGGGGGGGGGGGG	819 th (tie)	1		
5							
			G <mark>CTGATAGGAT</mark> GGG <mark>TTGTA</mark> GGT <mark>C</mark> TAGGGGGGGGG <mark>CC</mark>	34 th (tie)	7		
	VEGER-2	24 684	G <mark>CTGATAGGA</mark> TGGG <mark>TTGTAGGTC</mark> TAGGGGGGGGGGG	34 th (tie)	7	15	0.061
	VLOIN Z	27,007	G <mark>CTGATAGGAT</mark> GGG <mark>TTGTAGGTC</mark> GTAGGGGGGGGG <mark>CC</mark>	824 th (tie)	1		0.001
			G <mark>C</mark> TGA <mark>TAGGA</mark> TGGG <mark>TTGTAGGTC</mark> TAGGGGGGG <mark>CC</mark>	824 th (tie)	1		

Table S3. Abundance distribution of Apt02 families (5'-<u>GCTGATAGGATGGGTTGTAGGTCTAGGGGGGGGG</u>XXX-3') at each round



Fig. S1 Schematic of alternating consecutive selection of DNA aptamers using VEGFR-1 and VEGFR-2 immobilized on magnetic beads, referred to as MB1 and MB2, respectively, with deep sequencing analysis.



Fig. S2 SPR sensorgrams used to determine the binding affinities according to single-cycle kinetic analysis.



Fig. S3 SPR sensorgrams of Apt02, Apt02-scr, A35 binding to VEGFR-1.



Fig. S4 *In vitro* tube formation assay using human umbilical vein endothelial cells (HUVECs) on a three-dimensional gel consisting of diluted Matrigel. The cells were treated with Apt01 (20 μ M), Apt02 (20 μ M), A35 (20 μ M) or VEGF165 (20 ng/mL, 0.52 nM). (A) Representative images of tube formation of human umbilical vein endothelial cells (HUVECs) on Matrigel at 4 h. Scale bars are 0.5 mm. (B) Number of mesh in the images of the HUVECs networks at 4 h. (n=3 plots). * *P* < 0.05 as compared to control.



Fig. S5 Inhibition of HUVEC tubule growth by fruquintinib at 5 h. The cells were treated by Apt02 (20 μ M), or VEGF165 (20 ng/mL, 0.52 nM) with or without highly selective small molecule inhibitor of VEGFR tyrosine kinases, fruquintinib (10 μ M). Number of mesh of the HUVECs networks was counted at 5 h. (n=3 plots). * *P* < 0.05 as compared to Apt02-treated group without inhibitor.